PET tracer starts phase I trial:
This article was originally published in Clinica
Executive Summary
FluoroPharma is to begin phase I clinical trials of its imaging agent BFPET, following US institutional review board approval of the proposed studies. The planned trial will evaluate safety, distribution, and dosimetry of BFPET as a positron emission tomography (PET) blood flow tracer for myocardial perfusion imaging in healthy subjects. More than nine million patients undergo myocardial perfusion imaging - the standard test to assess coronary artery disease - annually in the US. Boston, Massachusetts-based FluoroPharma is a subsidiary of QuantRx.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.